Seliciclib

DRUG3 trials

Sponsors

Cyclacel Pharmaceuticals, Inc., M.D. Anderson Cancer Center, Cedars-Sinai Medical Center

Conditions

Breast CancerCushing DiseaseNon-small Cell Lung Cancer

Phase 1

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

WithdrawnNCT01333423

M.D. Anderson Cancer CenterBreast Cancer

Start: 2012-09-30Updated: 2012-06-26

Phase 2

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

TerminatedNCT00372073

Cyclacel Pharmaceuticals, Inc.Non-small Cell Lung Cancer

Start: 2006-08-09End: 2009-04-07Updated: 2021-12-22

Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

RecruitingNCT03774446

Cedars-Sinai Medical CenterCushing Disease

Start: 2018-11-02End: 2026-08-31Target: 13Updated: 2025-09-11